Use of Adalimumab in a Patient with Juvenile Idiopathic Arthritis Refractory to Etanercept: a Case Report and Literature Review
Journal: Austin Pediatrics (Vol.1, No. 2)Publication Date: 2014-05-27
Authors : Shih-Chieh Wei; Chih-Fang Huang; Shiau-Ru Chiou; Ho-Chang Kuo;
Page : 1-3
Keywords : Juvenile idiopathic arthritis; Adalimumab; Etanercept;
Abstract
In this report, we present a child patient diagnosed with juvenile idiopathic arthritis (JIA) refractory to disease-modifying anti-rheumatic drugs (DMARDs), Methylprednisolone pulse therapy, and the TNF-a-inhibitor etanercept, with a significant improvement in hematologic abnormalities after the introduction of adalimumab.
Other Latest Articles
- Using Brochures as Educational Tools to Promote Routine HIV Testing in Youth
- Nevus Sebaceous
- A Case of Neonatal Diabetes Presentation, Diagnosis and Management
- Calcifying Aponeurotic Fibroma of the Chest Wall in a 5-Month-Old Infant: A Case Report and Review of the Literature
- SUMMARY OF ECONOMIC CATEGORIES “EXPENSES”, “COSTS”
Last modified: 2017-09-01 18:16:40